Nonadditivity in human microsomal drug metabolism revealed in a study with coumarin 152, a polyspecific cytochrome P450 substrate

被引:6
作者
Dangi, Bikash [1 ]
Davydova, Nadezhda Y. [1 ]
Vavilov, Nikita E. [2 ]
Zgoda, Victor G. [2 ,3 ]
Davydov, Dmitri R. [1 ]
机构
[1] Washington State Univ, Dept Chem, Pullman, WA 99164 USA
[2] Inst Biomed Chem, Moscow, Russia
[3] Skolkovo Inst Sci & Technol, Skolkovo, Moscow Region, Russia
关键词
Cytochrome P450; Coumarin; 152; fluorogenic substrates; human liver microsomes; drug metabolism; inhibition; PHOTOPHYSICAL PROPERTIES; LIVER-MICROSOMES; UNUSUAL BEHAVIOR; P450; INHIBITION; ENZYMES; MECHANISMS; DISCOVERY; KINETICS; NONPOLAR;
D O I
10.1080/00498254.2020.1775913
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We closely characterized 7-Dimethylamino-4-trifluromethylcoumarin (Coumarin 152, C152), a substrate metabolized by multiple P450 species, to establish a new fluorogenic probe for the studies of functional integration in the cytochrome P450 ensemble. Scanning fluorescence spectroscopy and LC/MS-MS were used to characterize the products of N-demethylation of C152 and optimize their fluorometric detection. The metabolism of C152 by the individual P450 species was characterized using the microsomes containing cDNA-expressed enzymes. C152 metabolism in human liver microsomes (HLM) was studied in a preparation with quantified content of eleven P450 species. C152 is metabolized by CYP2B6, CYP3A4, CYP3A5, CYP2C19, CYP1A2, CYP2C9, and CYP2C8 listed in the order of decreasing turnover. The affinities exhibited by CYP3A5, CYP2C9, and CYP2C8 were lower than those characteristic to the other enzymes. The presumption of additivity suggests the participation of CYP3A4, CYP2B6, and CYP2C19 to be 84, 8, and 0.2%, respectively. Contrary to this prediction, inhibitory analysis identified CYP2C19 as the principal C152-metabolizing enzyme. We thoroughly characterize C152 for the studies of drug metabolism in HLM and demonstrate the limitations of the proportional projection approach by providing an example, where the involvement of individual P450 species cannot be predicted from their content.
引用
收藏
页码:1393 / 1405
页数:13
相关论文
共 45 条
[11]   Toward a systems approach to cytochrome P450 ensemble: interactions of CYP2E1 with other P450 species and their impact on CYP1A2 [J].
Davydova, Nadezhda Y. ;
Dangi, Bikash ;
Maldonado, Marc A. ;
Vavilov, Nikita E. ;
Zgoda, Victor G. ;
Davydov, Dmitri R. .
BIOCHEMICAL JOURNAL, 2019, 476 :3661-3685
[12]   Intraindividual Variation and Correlation of Cytochrome P450 Activities in Human Liver Microsomes [J].
Fang, Yan ;
Gao, Jie ;
Wang, Tong ;
Tian, Xin ;
Gao, Na ;
Zhou, Jun ;
Zhang, Hai-Feng ;
Wen, Qang ;
Jin, Han ;
Xing, Yu-Rong ;
Qiao, Hai-Ling .
MOLECULAR PHARMACEUTICS, 2018, 15 (11) :5312-5318
[13]   DeepXSS: Cross Site Scripting Detection Based on Deep Learning [J].
Fang, Yong ;
Li, Yang ;
Liu, Liang ;
Huang, Cheng .
PROCEEDINGS OF 2018 INTERNATIONAL CONFERENCE ON COMPUTING AND ARTIFICIAL INTELLIGENCE (ICCAI 2018), 2018, :47-51
[14]   Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes [J].
Gao, Na ;
Tian, Xin ;
Fang, Yan ;
Zhou, Jun ;
Zhang, Haifeng ;
Wen, Qiang ;
Jia, Linjing ;
Gao, Jie ;
Sun, Bao ;
Wei, Jingyao ;
Zhang, Yunfei ;
Cui, Mingzhu ;
Qiao, Hailing .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 92 :86-97
[15]   Mechanism of cytochrome P450-3A inhibition by ketoconazole [J].
Greenblatt, David J. ;
Zhao, Yanli ;
Venkatakrishnan, Karthik ;
Duan, Su X. ;
Harmatz, Jerold S. ;
Parent, Sarah J. ;
Court, Michael H. ;
von Moltke, Lisa L. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (02) :214-221
[16]   Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro [J].
Greenblatt, David J. ;
Venkatakrishnan, Karthik ;
Harmatz, Jerold S. ;
Parent, Sarah J. ;
von Moltke, Lisa L. .
XENOBIOTICA, 2010, 40 (10) :713-720
[17]   THE USE OF PRINCIPAL COMPONENT ANALYSIS TO RESOLVE THE SPECTRA AND KINETICS OF CYTOCHROME-C OXIDASE REDUCTION BY 5,10-DIHYDRO-5-METHYL PHENAZINE [J].
HALAKA, FG ;
BABCOCK, GT ;
DYE, JL .
BIOPHYSICAL JOURNAL, 1985, 48 (02) :209-219
[18]   Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5 [J].
Kaspera, Ruediger ;
Naraharisetti, Suresh B. ;
Evangelista, Eric A. ;
Marciante, Kristin D. ;
Psaty, Bruce M. ;
Totah, Rheem A. .
BIOCHEMICAL PHARMACOLOGY, 2011, 82 (06) :681-691
[19]   New potent and selective cytochrome P4502B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis [J].
Korhonen, L. E. ;
Turpeinen, M. ;
Rahnasto, M. ;
Wittekindt, C. ;
Poso, A. ;
Pelkonen, O. ;
Raunio, H. ;
Juvonen, R. O. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 150 (07) :932-942
[20]   Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple [J].
Krohn, KA ;
Link, JM .
NUCLEAR MEDICINE AND BIOLOGY, 2003, 30 (08) :819-826